NDAORALFOR SUSPENSIONPriority Review
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
AQNEURSA (levacetylleucine) by IntraBio is p-glycoprotein inhibitors [moa]. First approved in 2024.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AQNEURSA (levacetylleucine) is an oral suspension small molecule approved in September 2024 that acts as a P-glycoprotein inhibitor. The drug's mechanism suggests modulation of drug transporter activity, though specific indications are not yet publicly detailed. Patient population and therapeutic area remain to be clarified as the product enters its growth phase.
Growth11.0 years to LOE
Recent approval and no current competitive pressure position this as a growth-stage product; early commercial teams will focus on market development and physician education.
Mechanism of Action
P-Glycoprotein Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
Ataxia-Telangiectasia (A-T)
Career Relevance
AQNEURSA offers entry or mid-career professionals a rare opportunity: a newly approved product with zero competitive pressure and 11 years of patent protection. Early movers in brand, sales, and medical affairs roles will build the market from ground level and shape long-term franchise success.
Brand Manager
Worked on AQNEURSA at IntraBio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.